Español
Abstract
In this review we discuss recent developments in the process of production of the disease, through the analysis of recently described pathogenic mechanisms. Lymphocyte (T, CD4+) subpopulations, TH I and TH2 are associated with the production of interleuquins, some of them newly described are related with two phases in the progression of the infection: "protection" and "progression". Based on tbis information, newly designed therapeutic approaches have being deviced, base on the possibility of using IL-12 as a therapeutic drug. The first Phase I clinical trials have recently started. Also the possibility of keeping high levels of IL- 12 as a response to inmunogens has been planned as a new possibility of developing a vaccine. This idea can be further developed with the use of small amounts of antigen or through the use of nacked DNA.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
